Dr. Andres
Gutierrez, Oncolytics' Chief Medical Officer, to present on
the clinical progress and robust safety findings of using reovirus
as an immuno-oncology viral agent to treat cancer
CALGARY and SAN DIEGO, Sept. 19,
2017 /PRNewswire/ - Oncolytics Biotech® Inc.
(TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech
company developing REOLYSIN®, a first-in-class,
intravenously delivered immuno-oncolytic virus that activates the
innate and adaptive immune systems, today announced that it will
present at the Phacilitate Immuno-Oncology Frontiers
Conference. Dr. Andres
Gutierrez, Oncolytics' Chief Medical Officer, will present
at 4:00 pm CEST on September 21, 2017 at the Maritim Proarte Hotel.
The conference takes place on September
20th and 21st in Berlin,
Germany.
Dr. Gutierrez will highlight the role of REOLYSIN in the
activation of the immune system and the induction of an inflamed
tumor phenotype in the tumor microenvironment. His
presentation will also review certain historical clinical programs,
highlight the positive survival data from the IND 213 study in
metastatic breast cancer (mBC) and the pooled safety database – the
largest of any oncolytic virus.
"We want to share our extensive experience with REOLYSIN in the
clinic to illustrate the specific expertise and efforts required to
develop an oncolytic virus for intravenous administration and
systemic exposure in oncology," said Dr. Gutierrez. "This
experience helped us define a clear regulatory pathway for
registration in metastatic breast cancer. With an overall agreement
with the FDA on the phase 3 study design, details of the pivotal
registration study will be made available following evaluation and
completion of discussions with clinical advisors and potentially
partners, as well as European regulators."
The Phacilitate Immuno-Oncology Frontiers conference hosts over
300 industry decision-makers and key external stakeholders to come
together discuss and define a strategic roadmap to success for
immuno-oncology developers, ensuring European patients gain access
to the game-changing biotherapeutics of tomorrow. Immuno-Oncology
frontiers Berlin is the only
European event that offers extensive coverage of the latest
emerging science whilst placing it in its wider strategic context
as the basis of tomorrow's successful business and
commercialisation models.
About REOLYSIN
REOLYSIN® is a
non-pathogenic, proprietary isolate of the unmodified reovirus: a
first-in-class intravenously delivered immuno-oncolytic virus for
the treatment of solid tumors and hematological malignancies. The
compound induces selective tumor lysis and promotes an inflamed
tumor phenotype through innate and adaptive immune responses to
treat a variety of cancers.
About Oncolytics Biotech Inc.
Oncolytics is a
biotechnology company developing REOLYSIN, an intravenously
delivered immuno-oncolytic virus. The compound induces selective
tumor lysis and promotes an inflamed tumor phenotype through innate
and adaptive immune responses to treat a variety of cancers.
Oncolytics' clinical development program emphasizes three pillars:
chemotherapy combinations to trigger selective tumor lysis;
immuno-therapy combinations to produce adaptive immune responses;
and immune modulator (IMiD) combinations to facilitate innate
immune responses. Oncolytics is currently planning its first
registration study in metastatic breast cancer, as well as studies
in combination with checkpoint inhibitors as well as targeted and
IMiD therapies in solid and hematological malignancies. For
further information about Oncolytics, please
visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements,
within the meaning of Section 21E of the Securities Exchange Act of
1934, as amended. Forward-looking statements, including the
Company's belief as to the potential of REOLYSIN® as a
cancer therapeutic; the Company's expectations as to the success of
its research and development programs in 2017 and beyond, the
Company's planned operations, the value of the additional patents
and intellectual property; the Company's expectations related to
the applications of the patented technology; the Company's
expectations as to adequacy of its existing capital resources; the
design, timing, success of planned clinical trial programs; and
other statements related to anticipated developments in the
Company's business and technologies involve known and unknown risks
and uncertainties, which could cause the Company's actual results
to differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and
development projects, the efficacy of REOLYSIN as a cancer
treatment, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize
REOLYSIN, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process
and general changes to the economic environment. Investors should
consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned against placing undue reliance
on forward-looking statements. The Company does not undertake to
update these forward-looking statements, except as required by
applicable laws.
SOURCE Oncolytics Biotech Inc.